Bitopertin: the good news and bad news.
New York Langone Medical Center, Nathan Kline Institute for Psychiatric Research, Orangeburg, New York.
Donald C
DC
Goff
D014150:Antipsychotic Agents / Q000627:therapeutic use*; D005260:Female; D050487:Glycine Plasma Membrane Transport Proteins / Q000037:antagonists & inhibitors*; D006801:Humans; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D013450:Sulfones / Q000627:therapeutic use*
C550631:(4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl)(5-methanesulfonyl-2-(2,2,2-trifluoro-1-methylethoxy)phenyl)methanone; D014150:Antipsychotic Agents; D050487:Glycine Plasma Membrane Transport Proteins; D010879:Piperazines; C493268:SLC6A9 protein, human; D013450:Sulfones